Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04643639
Other study ID # The EndoSorb Study
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 16, 2020
Est. completion date October 19, 2022

Study information

Verified date March 2021
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this randomized, open-label study, the investigators will assess whether CytoSorb hemoperfusion will prevent or attenuate the development of immunoparalysis in healthy volunteers undergoing repeated experimental endotoxemia.


Description:

Sepsis is an inflammatory syndrome with high mortality rates and increasing incidence. Sepsis-induced immunoparalysis, increasingly recognized as the overriding immune disorder in sepsis patients, attributes significantly to late mortality in sepsis patients. The investigators hypothesize that 'blood purification' techniques targeted at the removal of excess circulating cytokines, such as the CytoSorb hemoperfusion device, might prevent or attenuate the development of immunoparalysis. The objective of this trial is to determine the effects of CytoSorb hemoperfusion on the development of immunoparalysis in a repeated experimental endotoxemia model in healthy male volunteers. To this end, 24 healthy male volunteers subjects will be randomized in a 1:1 fashion into one of two treatment groups (active or control). Both study groups will undergo two endotoxin challenges, separated by seven days. To this end, endotoxin (LPS) will be administered as a bolus of 1 ng/kg, followed by continuous infusion of 0.5 ng/kg/hr for three hours. The active group will be treated with CytoSorb hemoperfusion during the first endotoxin challenge, whereas the control group will receive no additional treatment. During both endotoxin challenges, blood samples will be obtained serially to measure levels of circulating cytokines and other inflammatory mediators.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date October 19, 2022
Est. primary completion date October 19, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Provide written informed consent - Male - Age = 18 and = 35 years - Healthy (as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and routine clinical laboratory parameters) Exclusion Criteria: - Use of any medication - Smoking - Known anaphylaxis or hypersensitivity to any (non-)investigational products or their excipients. - History or signs of atopic syndrome (asthma, rhinitis with medication and/or eczema) - History or signs of hematological disease - History or signs of thromboembolic disorders - History of (intracranial) aneurysmal or hemorrhagic diseases - History of heparin-induced thrombocytopenia (HIT) - Thrombocytopenia (<150*109/ml) or anemia (hemoglobin < 8.0 mmol/L) - History, signs or symptoms of cardiovascular disease, in particular: - Previous spontaneous vagal collapse - History of atrial or ventricular arrhythmia - Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrio-ventricular block or a complete left bundle branch block - Hypertension (defined as RR systolic > 160 or RR diastolic > 90 mmHg) - Hypotension (defined as RR systolic < 100 or RR diastolic < 50 mmHg) - Renal impairment (defined as plasma creatinine >120 µmol/l) - Liver enzyme abnormalities (above 2x the upper limit of normal) - Medical history of any disease associated with immune deficiency - Signs of infection (CRP > 20 mg/L, WBC > 12x109/L or < 4x109/L) - Clinically significant acute illness, including infections or trauma, within 1 month of the first endotoxin challenge - Previous (participation in a study with) endotoxin (LPS) administration - Any vaccination within 3 months within of the first endotoxin challenge - Participation in a drug trial or donation of blood within 3 months prior to first endotoxin challenge - Recent hospital admission or surgery with general anesthesia within 3 months prior to first endotoxin challenge - Use of recreational drugs within 1 month of the first endotoxin challenge - Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.

Study Design


Intervention

Device:
CytoSorb hemoperfusion
Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.

Locations

Country Name City State
Netherlands Radboud University Medical Center Nijmegen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center CytoSorbents Europe GmbH

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Between group differences in plasma interleukin (IL)-6 levels during the second endotoxin challenge. Blood samples will be obtained at predefined time points before, during and after endotoxin administration to assess plasma levels (in pg/mL) of circulating inflammatory mediatiors. To assess between group differences, the area under the curve (AUC) of the time concentration curve (expressed in arbitrary units) of each inflammatory mediator will be calculated. Samples will be obtained starting 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in plasma levels of other inflammatory cytokines during the second endotoxin challenge. Interleukin (IL)-6, IL-8, IL-10, Monocyte Chemoattractant Protein (MCP)-1, C-X-C motif chemokine ligand (CXCL)-10, Macrophage Inflammatory Protein (MIP)-1a, MIP-1ß, and Granulocyte Colony-Stimulating Factor (G-CSF) Samples will be obtained starting 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in mHLA-DR expression Differences in Human Leukocyte Antigen (HLA)-DR expression on monocytes will be assessed using flowcytometry. 1 hour before, 3 hours after and 6 hours after endotoxin administration
Secondary Between group differences in norepinephrine sensitivity To assess the effects of CytoSorb hemoperfusion on norepinephrine sensitivity, norepinephrine will be administered in increasing dosages (0.025; 0.05 and 0.1 ?) for 5 minutes per dose. Blood pressure will be recorded continuously with an arterial catheter. One hour before and 4 hours after endotoxin administration during the first endotoxin challenge
Secondary Cytokine clearance by the adsorber Blood samples will be obtained from the afferent and efferent tubing of the CytoSorb adsorber to calculate clearance of cytokines by the adsorber Every 30 minutes until cessation of hemoperfusion (six hours after endotoxin administration)
Secondary Between group differences in endotoxemia-induced metabolic activity of platelets Blood samples will be collected in citrated tubes to allow assessment of ATP production by platelets. 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in endotoxemia-induced clinical symptoms Clinical symptoms will be scored on a Likert scale (ranging from 0 to 5) in a composite endpoint consisting of headache, nausea, shivering, muscle soreness and lower back pain. Higher numbers indicate more severe symptoms. Every 30 minutes from 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in body temperature Body temperature will be assessed using tympanic temperature measurements Every 30 minutes from 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in blood pressure Systolic, diastolic and mean arterial pressure will be measured continuously using a radial artery catheter. From 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in heart rate Heart rate will be recorded continuously using a 3-lead ECG. From 1 hour prior until 8 hours after endotoxin administration
Secondary Between group differences in markers of endothelial injury Vascular cell adhesion protein (VCAM)-1 and Intercellular Adhesion Molecule (ICAM)-1 Samples will be obtained starting 1 hour prior until 8 hours after endotoxin administration
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3